Historical infectious disease vaccine benchmarks
Established diseases had higher progression rates
The gap between new and established disease areas widened in later phases.
Phase 1 → 2
New diseases 55% Established diseases 57% 49%Phase 2 → 3
New diseases 31% Established diseases 48% 35%Phase 3 → filing
New diseases 43% Established diseases 82% 67%Rates use programs with recorded outcomes for each phase, counted by indication. HIV treatment is excluded. BIO’s published rates cover a separate 2013–2022 cohort.
Gosset trial coverage
Vaccine trial coverage across registries
Matches by registration ID, November 18, 2026.
ClinicalTrials.gov vaccine search
4,288 of 4,355 registrations found in Gosset
Industry-led interventional records matched by vaccine terms in titles, intervention names or aliases, or ClinicalTrials.gov’s MeSH indexing. Of these, 4,279 list early Phase 1 through Phase 4. Search matches can include vaccine comparators.
| Historical Pharmapremia export | In Gosset | Absent from Gosset |
|---|---|---|
| In the export | 844 | 1 |
| Outside the export | 3,444 | 66 |
The historical export and the registry search cover different cohorts and time windows.
| Registry check | IDs checked | In Gosset |
|---|---|---|
| EU Clinical Trials Register search, industry vaccine trials | 5 | 5 |
| China spot check, selected CDE and ChiCTR records | 7 | 7 |
The EU searches returned six results. Five were industry vaccine studies for either disease. Some studies appear in multiple registries, so each row counts registrations within its own source.